Pharma major Lupin Ltd expects continued growth in US sales this fiscal on its rising branded and generics business, a top official said late on Thursday.
The Mumbai-based drugmaker had reported about 37 percent rise in US sales in FY10 to 16.5 billion rupees.
"We expect sales to rise more than 20 percent in the current year," S. Ramesh, president, finance and planning, told Reuters but declined to be pinned down to a definite figure.
"If the past is a prescription of future performance, then we would continue to grow as we have done in all geographies including US."
Lupin's net sales in regulated markets like the US and Europe grew 40 percent to 4.96 billion rupees in the April-June quarter this year over 3.5 billion rupees in FY10.
"There are a lot of things happening in the US but I cannot comment about acquisition plans at this moment," he added.
Lupin's performance in the highly competitive US market remains robust while its Indian peers have seen sluggish growth.
Glenmark Pharmaceuticals' US unit reported a 6 percent rise in revenue to 1.82 billion rupees in April-June while Aurobindo Pharma's US operating income grew 6.4 percent in the same period to 2.16 billion rupees.
The Mumbai-based drugmaker had reported about 37 percent rise in US sales in FY10 to 16.5 billion rupees.
"We expect sales to rise more than 20 percent in the current year," S. Ramesh, president, finance and planning, told Reuters but declined to be pinned down to a definite figure.
"If the past is a prescription of future performance, then we would continue to grow as we have done in all geographies including US."
Lupin's net sales in regulated markets like the US and Europe grew 40 percent to 4.96 billion rupees in the April-June quarter this year over 3.5 billion rupees in FY10.
"There are a lot of things happening in the US but I cannot comment about acquisition plans at this moment," he added.
Lupin's performance in the highly competitive US market remains robust while its Indian peers have seen sluggish growth.
Glenmark Pharmaceuticals' US unit reported a 6 percent rise in revenue to 1.82 billion rupees in April-June while Aurobindo Pharma's US operating income grew 6.4 percent in the same period to 2.16 billion rupees.
No comments:
Post a Comment